SynBiotic Logo
DE000A3E5A59
A3E5A5
SBX.DE

SynBiotic

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.


  • SYNBIOTIC SE: subsidiary Hempro International applies for preliminary insolvency proceedings

    Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » Altro su finanzen.net


  • SynBiotic share plunges almost 20% after US cannabis reclassification

    The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » Altro su finanzen.net


  • Synbiotic shares more than double since Friday after anchor investor steps in

    Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » Altro su de.investing.com

Nel 2022, SynBiotic ha già distribuito +0,30 di dividendi. L'ultimo pagamento è avvenuto a luglio 2022.

Dati finanziari dell'azienda

Nell'ultimo anno, SynBiotic ha registrato ricavi pari a +3,86 Mio e un utile netto di 10,63 Mio
(EUR) 2023
YoY
Ricavi +3,86 Mio 52,71%
Utile lordo +1,51 Mio 57,83%
Utile netto 10,63 Mio 56,36%
EBITDA 7,12 Mio 4,85%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+3,45 Mio
Numero di azioni
4,75 Mio
Massimo/minimo a 52 settimane
+3,85 - +0,50
Dividendi No
Beta
0,68
Rapporto P/E
0,32
Rapporto PEG
0,00
Rapporto P/B
+0,22
Rapporto P/S
+0,89

Profilo aziendale

SynBiotic SE beschäftigt sich mit der Entwicklung von Medikamenten und rezeptfreien Wellness-Produkten auf der Basis von Cannabinoiden. Das Unternehmen konzentriert sich auf die synthetische Herstellung von Cannabinoiden, die Entwicklung von Medikamenten, Nahrungsergänzungsmitteln und kosmetischen Produkten. Das Unternehmen war früher als Ledgertech SE bekannt und änderte seinen Namen in Ledgertech SE. SynBiotic SE hat seinen Sitz in München, Deutschland.

Nome
SynBiotic
CEO
Daniel Kruse
Sede centrale Düsseldorf, nw
Germania
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
07/01/2021
Dipendenti 79

Simboli di borsa

Borsa Simbolo
XETRA
SBX.DE
Frankfurt
SBX.F
Düsseldorf
SBX.DU
Hamburg
SBX.HM
München
SBX.MU
SIX
SBX.SW
🍪

Parqet  usa i cookie. Scopri di più